Omeros' OMS721 Receives FDA's ODD to Treat Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)
Shots:
- The ODD is based on Omeros’ P-III program assessing OMS721 in patients with HSCT-TMA. Additionally- OMS721 is being evaluated in ongoing P-III program for IgA nephropathy- and aHUS respectively
- With the above designation OMS721 will serve in both prevention and treatment of HSCT-TMA in EU and the US. OMS721 also received ODD in IgA nephropathy- and aHUS- BT for IgA nephropathy & FTD for aHUS
- Omeros’ OMS721 is a mAb targeting MASP-2 while- holding WW rights for MASP-2 and all therapeutics targeting MASP-2 & developing small molecules for it. OMS721 also identified MASP-3 (for converting pro-factor D to factor D)
/ article | Ref: Omeros | Image: The Business Journals
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com